Reported 4 months ago
J.P. Morgan's global investment strategist, Madison Faller, notes repeating historical patterns indicating potential stock market strength. Two stocks identified by JPMorgan analysts for up to 210% upside are Kyverna Therapeutics (KYTX) and Structure Therapeutics (GPCR), both also rated as ‘Strong Buys’ by the analyst consensus. Kyverna is focused on autoimmune diseases with a potential CAR-T therapy, while Structure Therapeutics is developing new orally dosed therapeutic agents. Analysts have positive ratings for both stocks, with expectations of significant gains in the coming year.
Source: YAHOO